BRAF

Repurposing research signal · ALTERLACTONE · v0.1

Deterministic research signal for ALTERLACTONE. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALTERPORRIOL G/H · v0.1

Deterministic research signal for ALTERPORRIOL G/H. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALVOCIDIB · v0.1

Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ARQ-736 · v0.1

Deterministic research signal for ARQ-736. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALTERNARIENONIC ACID · v0.1

Deterministic research signal for ALTERNARIENONIC ACID. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALTERTOXIN I · v0.1

Deterministic research signal for ALTERTOXIN I. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALTERSOLANOL A · v0.1

Deterministic research signal for ALTERSOLANOL A. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALTERNARIOL · v0.1

Deterministic research signal for ALTERNARIOL. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · CEP-32496 · v0.1

Deterministic research signal for CEP-32496. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · CANERTINIB · v0.1

Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · AST-487 · v0.1

Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · BMS-387032 · v0.1

Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Repurposing research signal · ALTENUSIN · v0.1

Deterministic research signal for ALTENUSIN. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.